Cue Announces $30 Million Funding Contract from U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority for development and regulatory validation of over-the-counter and professional use influenza and respiratory pathogen cartridges to help manage seasonal and pandemic influenza.

Cue Health Inc. (“Cue”), a healthcare technology company developing a range of diagnostic products for professionals and consumers, announced today it has raised $45MM in Series B financing. The financing will be used to complete development and fund the initial set of FDA 510(k) clinical studies for Cue’s first set of diagnostic products.

Cue Health Receives ISO 13485 Certification for the design and development, manufacture and distribution of in-vitro diagnostic medical devices used in the detection, diagnosis and management of infectious diseases, women’s health, cardiovascular health, wellness, and other diseases and conditions.

Cue Health Inc. today announced a collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, (Janssen) to address a significant global health need for HIV viral load testing using Cue's Lab-In-A-Box proprietary molecular diagnostics platform.